Cargando…

Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis

Ovarian cancer is the second leading cause of cancer-related deaths in women, with low five-year survival rates. Therefore, it is essential to seek new treatment options. Olaparib, a PARP inhibitor, has benefited many ovarian cancer patients, but olaparib is much less effective as a single agent in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yan, Wu, Tianyu, Hu, Xin, Xu, Simeng, Xiao, Di, Wu, Jingtao, Yan, Xinjian, Yang, Xiaoping, Li, Gaofeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2022
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795793/ https://www.ncbi.nlm.nih.gov/pubmed/35165509 http://dx.doi.org/10.7150/ijms.67027

Ejemplares similares

Inhibition of PKM2 Enhances Sensitivity of Olaparib to Ovarian Cancer Cells and Induces DNA Damage
por: Zhou, Sichun, et al.
Publicado: (2022)

Synergistic augmentation of osimertinib‐induced autophagic death by proguanil or rapamycin in bladder cancer
por: Xiao, Di, et al.
Publicado: (2023)

Phenformin and ataxia‐telangiectasia mutated inhibitors synergistically co‐suppress liver cancer cell growth by damaging mitochondria
por: Wu, Tianyu, et al.
Publicado: (2021)

Inhibitory role of proguanil on the growth of bladder cancer via enhancing EGFR degradation and inhibiting its downstream signaling pathway to induce autophagy
por: Xiao, Di, et al.
Publicado: (2022)

Synergistic antitumor efficacy of rMV-Hu191 and Olaparib in pancreatic cancer by generating oxidative DNA damage and ROS-dependent apoptosis
por: Zhang, Chu-di, et al.
Publicado: (2023)

Synthesis, Anti-Proliferative Evaluation and Mechanism of 4-Trifluoro Methoxy Proguanil Derivatives with Various Carbon Chain Length
por: Xu, Simeng, et al.
Publicado: (2021)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

Metformin Affects Olaparib Sensitivity through Induction of Apoptosis in Epithelial Ovarian Cancer Cell Lines
por: Gralewska, Patrycja, et al.
Publicado: (2021)

MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer
por: Yi, Jingyan, et al.
Publicado: (2019)

Atovaquone/proguanil‐induced autoimmune‐like hepatitis
por: Terziroli Beretta‐Piccoli, Benedetta, et al.
Publicado: (2017)

Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
por: Tommasi, Chiara, et al.
Publicado: (2011)

Olaparib in the management of ovarian cancer
por: Bixel, Kristin, et al.
Publicado: (2015)

Olaparib in Epithelial Ovarian Cancer
por: Anastasia, Paula J.
Publicado: (2016)

Plasmodium falciparum Malaria and Atovaquone-Proguanil Treatment Failure
por: Durand, Rémy, et al.
Publicado: (2008)

Atovaquone‐proguanil for treating uncomplicated Plasmodium falciparum malaria
por: Blanshard, Andrew, et al.
Publicado: (2021)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
por: Wiegmann, Anja, et al.
Publicado: (2022)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Pancytopenia due to proguanil toxicity in a returning traveller with fever
por: Jolink, Hetty, et al.
Publicado: (2010)

Paludrine (Proguanil) as a Suppressive and Prophylactic in P.-Vivax Infections
por: Desai, V. G.
Publicado: (1951)

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy
por: Tan, Kathrine R., et al.
Publicado: (2018)

Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil
por: Mueller, L., et al.
Publicado: (2017)

Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells
por: Gao, Jianwen, et al.
Publicado: (2021)

MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib
por: Whicker, Margaret E., et al.
Publicado: (2016)

AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
por: Meng, Xiangbing, et al.
Publicado: (2018)

Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer
por: Tang, Sangsang, et al.
Publicado: (2022)

Prognostic Role of DNA Damage Response Genes Mutations and their Association With the Sensitivity of Olaparib in Prostate Cancer Patients
por: Zhang, Dong, et al.
Publicado: (2022)

Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer
por: Jin, Yimei, et al.
Publicado: (2016)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

Synergistic effects of olaparib combined with ERCC1 on the sensitivity of cisplatin in non-small cell lung cancer
por: Xie, Kejie, et al.
Publicado: (2021)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates
por: van der Velden, Maarten, et al.
Publicado: (2017)

Cyclization-blocked proguanil as a strategy to improve the antimalarial activity of atovaquone
por: Skinner-Adams, Tina S., et al.
Publicado: (2019)

Profile of olaparib in the treatment of advanced ovarian cancer
por: Chase, Dana M, et al.
Publicado: (2016)

Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)
por: Mahdi, Haider, et al.
Publicado: (2021)

Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma
por: Yan, Xinjian, et al.
Publicado: (2020)

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer
por: Ledermann, Jonathan A, et al.
Publicado: (2016)

Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer
por: Zhong, Lixian, et al.
Publicado: (2018)

Olaparib-induced pseudoporphyria in a patient with ovarian cancer
por: Clark, Abigale, et al.
Publicado: (2023)

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer
por: Lee, Jung-Min, et al.
Publicado: (2015)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lg73q1kllp097otombjkoigi08